Trending...
- Citadel Credit Union's Business Banking Team Ready for August Launch
- Pennsylvania: Gov. Wolf Reacts to Dismantling of Roe v. Wade: "Elections Matter"
- REVIVV® Hair Growth Serum & Maskād® Post Procedure Face Masks by WETHRIVV™ Exhibit in Las Vegas
PHILADELPHIA--(BUSINESS WIRE)--iECURE, a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, and Center for Breakthrough Medicines (CBM) today announced the companies have entered into a strategic collaboration wherein CBM will produce and supply Good Manufacturing Practices (GMP)-grade adeno-associated virus (AAV) for use in iECURE's future clinical studies to enable development of iECURE's programs with the shared mission of accelerating the availability of these potential treatments to the patients.
"Our approach to gene editing relies on highly complex manufacturing processes, and we are eager to establish partnerships to ensure a reliable supply of GMP materials for future clinical development," said Paul Firuta, Chief Operating Officer of iECURE. "CBM was able to offer us significant amount of guaranteed capacity with scheduling flexibility and we are confident that they will be a strong partner with their state-of-the-art facilities and end-to end capabilities."
More on The PennZone
"iECURE's approach to gene editing is quite innovative and has the potential to bring significant hope to patients and families facing devastating diagnoses," said Audrey Greenberg, Chief Business Officer and Co-Founder of CBM. "Our ability to provide customizable clinical and commercial GMP manufacturing solutions integrated with industry-leading comprehensive in-process testing, quality control, and lot release programs allows us to support our partners like iECURE through the entirety of their product lifecycle and is aligned with our mission to bring life changing medicines to patients in need."
About iECURE
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of monogenic liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team's core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania's Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP's world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates. For more information, visit www.iecure.com and follow on LinkedIn.
More on The PennZone
About Center for Breakthrough Medicines (CBM)
CBM is a cell and gene therapy contract development and manufacturing organization (CDMO) based in the heart of Philadelphia's Cellicon Valley. CBM offers pre-clinical through commercial manufacturing capabilities including process development, plasmid DNA, viral vector, cell therapy and a full suite of testing and analytical capabilities. Through a single-source, end-to-end solution, CBM accelerates time to market without compromising quality.
Contacts
Investors:
David Garrett
dgarrett@iecure.com
Media:
Danielle Cantey
Canale Communications
danielle.cantey@canalecomm.com
"Our approach to gene editing relies on highly complex manufacturing processes, and we are eager to establish partnerships to ensure a reliable supply of GMP materials for future clinical development," said Paul Firuta, Chief Operating Officer of iECURE. "CBM was able to offer us significant amount of guaranteed capacity with scheduling flexibility and we are confident that they will be a strong partner with their state-of-the-art facilities and end-to end capabilities."
More on The PennZone
- High-Quality and Affordable Braces in Springfield Available from Exeter Orthodontics
- Southampton Dentures from DICE Dental Start at Only $499
- Always Ontime: Chaos City - Super Hero Graphic Novel with Neal Adams Cover Launches from Panopolis Metaverse
- Kelusky, Dietrich, Dawick, Gregoire, Lyle & Jeremy Thompson Nab Honors As NLL Opens Awards
- New Hampshire Becomes the 15th State to Require Personal Finance as a Core Academic Subject
"iECURE's approach to gene editing is quite innovative and has the potential to bring significant hope to patients and families facing devastating diagnoses," said Audrey Greenberg, Chief Business Officer and Co-Founder of CBM. "Our ability to provide customizable clinical and commercial GMP manufacturing solutions integrated with industry-leading comprehensive in-process testing, quality control, and lot release programs allows us to support our partners like iECURE through the entirety of their product lifecycle and is aligned with our mission to bring life changing medicines to patients in need."
About iECURE
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of monogenic liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team's core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania's Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP's world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates. For more information, visit www.iecure.com and follow on LinkedIn.
More on The PennZone
- Pennsylvania: Gov. Wolf Announces Federal Transit Administration Grant to Expand Access to Transportation Assistance Programs
- Virtual Workplace Platform Developer REACH Expands Executive Team, Positioning the Company to Drive International Growth
- Global Tax Management Launches GTM Training Institute to Address Tax Talent Gap
- Fulton Bank to Eliminate Consumer Non-Sufficient Funds and Extended Overdraft Fees
- Health Advisory: Protecting Yourself and Others from Monkeypox
About Center for Breakthrough Medicines (CBM)
CBM is a cell and gene therapy contract development and manufacturing organization (CDMO) based in the heart of Philadelphia's Cellicon Valley. CBM offers pre-clinical through commercial manufacturing capabilities including process development, plasmid DNA, viral vector, cell therapy and a full suite of testing and analytical capabilities. Through a single-source, end-to-end solution, CBM accelerates time to market without compromising quality.
Contacts
Investors:
David Garrett
dgarrett@iecure.com
Media:
Danielle Cantey
Canale Communications
danielle.cantey@canalecomm.com
Filed Under: Business
0 Comments
Latest on The PennZone
- BIOLASE ANNOUNCES SUPPORT FOR PROJECT HOME
- SwanBio Presents Design of Innovative Natural History Study Aimed to Evolve Understanding of Adrenomyeloneuropathy and Inform Future Treatments
- Avion Medical Skin Centres to offer innovative treatment for non-melanoma skin cancer patients
- Launch of Def Leppard beauty collection creating Hysteria in the makeup industry
- Pennsylvania: Gov. Wolf Applauds President Biden's Signing of First Comprehensive Gun Violence Package in Decades
- Direct Purchaser Plaintiffs Announce Settlements in In Re Generic Pharmaceutical Pricing Antitrust Litigation.
- Pennsylvania Commissions Condemn Supreme Court Decision, Remain Committed to Protecting the Right to Choose
- Pennsylvania: Gov. Wolf Shares Relief with Congressional Passage of Bipartisan Safer Communities Act, Urges Continued Momentum for Safer Communities
- Statement Pursuant to Section 19(a) of the Investment Company Act of 1940: DEX
- Ismail Sirdah' Guide To Landing Event Sponsorships
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Yext, Inc. (YEXT) Investors
- Pennsylvania: Gov. Wolf Reacts to Dismantling of Roe v. Wade: "Elections Matter"
- Children's Shoe Brand joins Soles4Souls in Ukrainian Refugee Relief Efforts
- The Data Economics Company announces partnership with Incradia to release the ReVerse franchise on Lydion-based Game Development Platform
- iTech offers 60-days free trial on expEDIum Medical Billing® product
- Pennsylvania: Gov. Wolf Commends Bipartisan Effort to Combat Surging Gun Violence, Eager for U.S. House to Send Bipartisan Safer Communities Act to President Biden's Desk
- Completion of funding round brings Metaphysiks one step closer to embodying the Metaverse
- On Anniversary of Surfside Tragedy, New Book Coaches Residents to Identify Warning Signs
- Citadel Credit Union's Business Banking Team Ready for August Launch
- Is Woody Biomass Fuel Making a Comeback?